文献速递银屑病与炎症性皮肤病

IL-17与IL-23抑制剂治疗银屑病起效速度的系统综述

Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-10-10

该系统综述纳入27项研究,定性合成并定量分析26项,评估IL-17与IL-23抑制剂治疗中重度斑块状银屑病达到PASI90的起效时间。主要目标为25%和50%患者达到PASI90的加权平均时间。结果显示IL-17抑制剂(brodalumab、ixekizumab)在获批剂量下起效时间短于IL-23抑制剂。

要点

  • brodalumab 210mg Q2W的25%和50%患者达PASI90时间最短,分别为3.5周和6.2周
  • ixekizumab 80mg Q2W为4.1周和7.4周,Q4W为4.6周和8.1周
  • IL-17抑制剂在获批剂量范围内起效时间短于IL-23抑制剂

核心结论

  • IL-17抑制剂在获批剂量下达到PASI90的起效时间短于IL-23抑制剂。

研究设计与样本

  • 系统综述,检索PubMed、Web of Science和EMBASE数据库,纳入27项研究进行数据提取和定性合成,其中26项进行定量分析。

主要发现

  • brodalumab 210mg Q2W的25%和50%患者达PASI90的加权平均时间分别为3.5周和6.2周。
  • ixekizumab 80mg Q2W的25%和50%患者达PASI90时间分别为4.1周和7.4周。
  • ixekizumab 80mg Q4W的25%和50%患者达PASI90时间分别为4.6周和8.1周。

关键数值与推荐

  • 主要目标为25%和50%银屑病患者达到PASI90所需的加权平均时间。
  • 检索词为psoriasis AND (ixekizumab OR secukinumab OR brodalumab OR risankizumab OR guselkumab OR tildrakizumab)。

临床怎么用

  • 临床选择生物制剂时可参考起效时间差异,IL-17抑制剂可能更快达到PASI90。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several novel biologics are available or in development for moderate-to-severe plaque psoriasis. These drugs may differ in time until Psoriasis Area and Severity Index (PASI) response is obtained. In this systematic review, we examined the time to onset of action for interleukin (IL)-17 and IL-23 agents in the treatment of psoriasis. The primary objective was the weighted mean time needed for 25% and 50% of patients with psoriasis to achieve PASI90. The medical databases PubMed, Web of Science and EMBASE were searched using the following terms: psoriasis AND (ixekizumab OR secukinumab OR brodalumab OR risankizumab OR guselkumab OR tildrakizumab). A total of 27 studies were included for data extraction and qualitative synthesis, and 26 of these were quantitatively analysed. The shortest time to 25% and 50% of patients to achieved PASI90 were seen with brodalumab 210 mg every 2 weeks (Q2W; 3.5 weeks and 6.2 weeks, respectively) followed by ixekizumab 80 mg Q2W (4.1 and 7.4 weeks, respectively) and ixekizumab 80 mg Q4W (4.6 and 8.1 weeks, respectively) dosages. In conclusion, clinical trials yielded shorter time to onset of action in studies assessing approved dosing ranges of IL-17 inhibitors compared with studies assessing IL-23 inhibitors.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Egeberg A, Andersen YMF, Halling-Overgaard AS, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 31465593. doi:10.1111/jdv.15920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。